|
US5158939A
(en)
*
|
1989-07-21 |
1992-10-27 |
Wisconsin Alumni Research Foundation |
Method of stimulating the immune systems of animals and compositions useful therefor
|
|
KR920703114A
(ko)
*
|
1989-07-14 |
1992-12-17 |
원본미기재 |
접합체 백신을 위한 시토킨 및 호르몬 운반체
|
|
US5498708A
(en)
*
|
1989-07-18 |
1996-03-12 |
Montefiore Medical Center |
Method of synthesizing polyesters
|
|
EP0482206A4
(en)
*
|
1990-04-12 |
1992-08-19 |
Japan Tobacco Inc. |
4,6-o-hydroxyphosphorylglucosamine derivative
|
|
US5653974A
(en)
*
|
1990-10-18 |
1997-08-05 |
Board Of Regents,The University Of Texas System |
Preparation and characterization of liposomal formulations of tumor necrosis factor
|
|
US5164375A
(en)
*
|
1991-09-27 |
1992-11-17 |
Merck & Company, Inc. |
Antifungal agent
|
|
US5648343A
(en)
*
|
1994-02-28 |
1997-07-15 |
The University Of Georgia Research Foundation |
Method for treating LPS-mediated disorders
|
|
US6218166B1
(en)
|
1994-12-09 |
2001-04-17 |
John Wayne Cancer Institute |
Adjuvant incorporation into antigen carrying cells: compositions and methods
|
|
US5681824A
(en)
*
|
1995-06-05 |
1997-10-28 |
Eisai Co., Ltd. |
Substituted liposaccharides useful in the treatment and prevention of endotoxemia
|
|
US6290971B1
(en)
*
|
1995-06-15 |
2001-09-18 |
Aventis Pasteur Limited |
Adjuvant compositions comprising a mineral salt and another immunostimulating compound
|
|
GB9706957D0
(en)
*
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
|
GB9820525D0
(en)
*
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
AU2001269695B2
(en)
|
2000-05-19 |
2007-02-15 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
|
|
US20030139356A1
(en)
*
|
2001-05-18 |
2003-07-24 |
Persing David H. |
Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
|
|
US20030138769A1
(en)
*
|
2000-08-16 |
2003-07-24 |
Birkett Ashley J. |
Immunogenic HBc chimer particles having enhanced stability
|
|
US20030185858A1
(en)
*
|
2001-08-15 |
2003-10-02 |
Birkett Ashley J. |
Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
|
|
US20030175863A1
(en)
*
|
2001-08-15 |
2003-09-18 |
Birkett Ashley J. |
Influenza immunogen and vaccine
|
|
US7361352B2
(en)
*
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
|
US6911434B2
(en)
*
|
2002-02-04 |
2005-06-28 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
|
|
JP2005516980A
(ja)
*
|
2002-02-04 |
2005-06-09 |
コリクサ コーポレイション |
新規な免疫エフェクター化合物
|
|
AU2003213640A1
(en)
*
|
2002-02-28 |
2003-09-16 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
|
AU2003251824B8
(en)
|
2002-07-08 |
2010-08-05 |
Corixa Corporation |
Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
|
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
DK1449535T3
(da)
*
|
2003-02-18 |
2006-09-11 |
Clinique La Prairie Res Sa |
Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
|
|
WO2006073921A2
(en)
*
|
2004-12-30 |
2006-07-13 |
The Rockefeller University |
Compositions and methods for enhanced dendritic cell maturation and function
|
|
US20060210590A1
(en)
|
2005-02-03 |
2006-09-21 |
Alk-Abello A/S |
Minor allergen control to increase safety of immunotherapy
|
|
US7622128B2
(en)
*
|
2005-12-13 |
2009-11-24 |
University Of Washington |
Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
|
|
HUE037808T2
(hu)
|
2006-09-26 |
2018-09-28 |
Infectious Disease Res Inst |
Szintetikus adalékanyagot tartalmazó vakcina kompozíció
|
|
US20090181078A1
(en)
*
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
|
US8747861B2
(en)
*
|
2007-08-02 |
2014-06-10 |
Biondvax Pharmaceuticals Ltd. |
Multimeric multiepitope influenza vaccines
|
|
US20090215908A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Toll like receptor (tlr) signaling antagonist
|
|
US20090215710A1
(en)
*
|
2007-09-24 |
2009-08-27 |
Reliance Life Sciences Pvt. Ltd. |
Carbohydrate based toll-like receptor (tlr) antagonists
|
|
US8637053B2
(en)
|
2007-12-03 |
2014-01-28 |
President And Fellows Of Harvard College |
Chlamydia antigens
|
|
CA2764374C
(en)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Synthetic glucopyranosyl lipid adjuvants
|
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
|
EP3632463A1
(en)
|
2011-04-08 |
2020-04-08 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
GB201106802D0
(en)
|
2011-04-21 |
2011-06-01 |
Allergy Therapeutics Ltd |
Process for preparing vaccine composition
|
|
ES2787455T3
(es)
|
2012-05-16 |
2020-10-16 |
Immune Design Corp |
Vacunas para el VHS-2
|
|
CA2900008A1
(en)
|
2013-02-07 |
2014-08-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
|
CN105658661B
(zh)
|
2013-02-20 |
2020-07-24 |
卑尔根技术交易股份公司 |
疫苗
|
|
BR112015025709A2
(pt)
|
2013-04-18 |
2017-07-18 |
Immune Design Corp |
monoterapia com gla para uso em tratamento de câncer
|
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
|
EP3632458B1
(en)
|
2013-07-26 |
2025-03-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
|
EP3681534A1
(en)
|
2017-09-13 |
2020-07-22 |
Sanofi Pasteur |
Human cytomegalovirus immunogenic composition
|
|
TW202003023A
(zh)
|
2018-03-12 |
2020-01-16 |
美商詹森藥物公司 |
針對尿路感染之疫苗
|
|
CN113195520A
(zh)
|
2018-08-24 |
2021-07-30 |
挪威西部创新股份有限公司 |
作为抗腹泻疫苗抗原的热稳定肠毒素突变体
|
|
EP4038091A1
(en)
|
2019-10-02 |
2022-08-10 |
Janssen Vaccines & Prevention B.V. |
Staphylococcus peptides and methods of use
|
|
FI4090363T3
(fi)
|
2020-01-16 |
2024-09-25 |
Janssen Pharmaceuticals Inc |
FimH-mutantti, sen koostumuksia ja sen käyttö
|
|
TW202241929A
(zh)
|
2021-01-12 |
2022-11-01 |
美商詹森藥物公司 |
ＦｉｍＨ突變體、其組成物及其用途
|
|
CA3215752A1
(en)
|
2021-04-01 |
2022-10-06 |
Janssen Pharmaceuticals, Inc. |
Production of e. coli o18 bioconjugates
|